<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NATRECOR- nesiritide injection, powder, lyophilized, for solution </strong><br>Scios LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use NATRECOR<span class="Sup">®</span> safely and effectively. See full prescribing information for NATRECOR<span class="Sup">®</span>.<br><br>NATRECOR<span class="Sup">®</span> (nesiritide) lyophilized powder for intravenous use<br>Initial U.S. Approval: 2001</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">NATRECOR<span class="Sup">®</span> is a natriuretic peptide indicated for the treatment of patients with acutely <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span> who have <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> at rest or with minimal activity. In this population, the use of NATRECOR<span class="Sup">®</span> reduced pulmonary capillary wedge pressure and improved symptomatic <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> when measured at 3 hours of infusion. (<a href="#s1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Monitor blood pressure closely during NATRECOR<span class="Sup">®</span> administration. (<a href="#s2">2</a>) </p>
<p class="Highlighta">The recommended dose of NATRECOR<span class="Sup">®</span> is an IV bolus of 2 mcg/kg followed by a continuous infusion of 0.01 mcg/kg/min. Do not initiate NATRECOR<span class="Sup">®</span> at a dose that is above the recommended dose. The bolus dose may not be appropriate for those with low SBP &lt;110 mm Hg or those recently treated with afterload reducers such as nitroglycerin. (<a href="#s2.1">2.1</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Single-use vial: 1.5 mg vial (<a href="#s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Persistent systolic blood pressure &lt;100 mm Hg prior to therapy because of an increased risk of symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#s4">4</a>, <a href="#s5.1">5.1</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components in the formulation. (<a href="#s4">4</a>, <a href="#s5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic shock</span> (<a href="#s4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: Not recommended for patients for whom vasodilating agents are not appropriate, or other conditions in which <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> is dependent upon venous return, or for patients suspected to have low cardiac filling pressures. (<a href="#s5.1">5.1</a>)</li>
<li>Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Monitor serum creatinine both during and after NATRECOR<span class="Sup">®</span> administration. (<a href="#s5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported. (<a href="#s5.3">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (≥3%) are <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>. (<a href="#s6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Scios LLC at 1-877-462-8732 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: use only if the potential benefit justifies any possible risk to the fetus (<a href="#s8.1">8.1</a>)</li>
<li>Nursing: use with caution (<a href="#s8.3">8.3</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Adjustments</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Preparation and Administration Instructions</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Chemical/Physical Interactions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Worsening of Renal Function</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NON-CLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">NATRECOR<span class="Sup">®</span> (nesiritide) is indicated for the treatment of patients with acutely <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span> who have <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> at rest or with minimal activity. In this population, the use of NATRECOR<span class="Sup">®</span> reduced pulmonary capillary wedge pressure and improved short term (3 hours) symptoms of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">NATRECOR<span class="Sup">®</span> (nesiritide) is for intravenous (IV) use only. There is limited experience with administering NATRECOR<span class="Sup">®</span> for longer than 96 hours. Monitor blood pressure closely during NATRECOR<span class="Sup">®</span> administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dosage</h2>
<p class="First">The recommended dose of NATRECOR<span class="Sup">®</span> is an IV bolus of 2 mcg/kg followed by a continuous infusion of 0.01 mcg/kg/min. Do not initiate NATRECOR<span class="Sup">®</span> at a dose that is above the recommended dose.</p>
<p>The loading dose may not be appropriate for those with low systolic blood pressure (SBP) &lt;110 mm Hg or for patients recently treated with afterload reducers.</p>
<p>The administration of the recommended dose of NATRECOR<span class="Sup">®</span> is a two step process:</p>
<p>Step 1. Administration of the IV Bolus</p>
<p><span class="Bold">After preparation of the infusion bag </span><span class="Italics">[see <a href="#s2.3">Dosage and Administration (2.3)</a>]</span>, withdraw the bolus volume (see <a href="#table1">Table 1</a>) from the NATRECOR<span class="Sup">®</span> infusion bag, and administer it over approximately 60 seconds through an IV port in the tubing.</p>
<p>Bolus Volume (mL) = Patient Weight (kg) / 3</p>
<a name="table1"></a><table width="80%">
<caption><span>Table 1:	NATRECOR<span class="Sup">®</span> Weight-Adjusted Bolus Volume Administered Over 60 Seconds (Final Concentration = 6 mcg/mL)</span></caption>
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Rrule" align="center">Patient Weight (kg)</th>
<th align="center">Volume of Bolus (mL=kg/3)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="center">60</td>
<td align="center">20.0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">70</td>
<td align="center">23.3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">80</td>
<td align="center">26.7</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">90</td>
<td align="center">30.0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">100</td>
<td align="center">33.3</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center">110</td>
<td align="center">36.7</td>
</tr>
</tbody>
</table>
<p>Step 2. Administration of the Continuous Infusion</p>
<p>Immediately following the administration of the bolus, infuse NATRECOR<span class="Sup">®</span> at a flow rate of 0.1 mL/kg/hr. This will deliver a NATRECOR<span class="Sup">®</span> infusion dose of 0.01 mcg/kg/min.</p>
<p>To calculate the infusion flow rate to deliver a 0.01 mcg/kg/min dose, use the following formula (see <a href="#table2">Table 2</a>):</p>
<p>Infusion Flow Rate (mL/hr) = Patient Weight (kg) × 0.1</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2:	NATRECOR<span class="Sup">®</span> Weight-Adjusted Infusion Flow Rate for a 0.01 mcg/kg/min Dose Following Bolus (Final Concentration = 6 mcg/mL)</span></caption>
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Rrule" align="center">Patient Weight (kg)</th>
<th align="center">Infusion Flow Rate (mL/hr)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="center">60</td>
<td align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">70</td>
<td align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">80</td>
<td align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">90</td>
<td align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">100</td>
<td align="center">10</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center">110</td>
<td align="center">11</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Adjustments</h2>
<p class="First">The dose-limiting side effect of NATRECOR<span class="Sup">®</span> is <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs during the administration of NATRECOR<span class="Sup">®</span>, reduce the dose of or discontinue NATRECOR<span class="Sup">®</span> and initiate other measures to support blood pressure (IV fluids, changes in body position). When symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, discontinue NATRECOR<span class="Sup">®</span>. Because <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> caused by NATRECOR<span class="Sup">®</span> may be prolonged (up to hours), a period of observation may be necessary before restarting the drug. NATRECOR<span class="Sup">®</span> may be subsequently restarted at a dose that is reduced by 30% (with no bolus administration) once the patient has stabilized.</p>
<p>Do not up-titrate NATRECOR<span class="Sup">®</span> more frequently than every 3 hours. Use central hemodynamic monitoring and do not exceed 0.03 mcg/kg/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Preparation and Administration Instructions</h2>
<p class="First"><span class="Bold">The NATRECOR<span class="Sup">®</span> bolus must be drawn from the prepared infusion bag. </span>Prime the IV tubing with 5 mL of the solution for infusion prior to connecting to the patient's vascular access port and prior to administering the bolus or starting the infusion.</p>
<ol>
<li>Reconstitute one 1.5 mg vial of NATRECOR<span class="Sup">®</span> by adding 5 mL of diluent removed from a pre-filled 250 mL plastic IV bag containing the diluent of choice. After reconstitution of the vial, each mL contains 0.32 mg of nesiritide. The following preservative-free diluents are recommended for reconstitution: 5% Dextrose Injection (D5W), USP; 0.9% Sodium Chloride Injection, USP; 5% Dextrose and 0.45% Sodium Chloride Injection, USP, or 5% Dextrose and 0.2% Sodium Chloride Injection, USP.</li>
<li>Do not shake the vial. Rock the vial gently so that all surfaces, including the stopper, are in contact with the diluent to ensure complete reconstitution. Use only a clear, essentially colorless solution.</li>
<li>
<span class="Bold">Withdraw the entire contents of the reconstituted NATRECOR<span class="Sup">®</span> vial </span>and add to the 250 mL plastic IV bag. This will yield a solution with a concentration of NATRECOR<span class="Sup">®</span> of approximately 6 mcg/mL. Invert the IV bag several times to ensure complete mixing of the solution.</li>
<li>Use the reconstituted solution within 24 hours, as NATRECOR<span class="Sup">®</span> contains no antimicrobial preservative. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Reconstituted vials of NATRECOR<span class="Sup">®</span> may be stored at 2 to 25°C (36 to 77°F) for up to 24 hours.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Chemical/Physical Interactions</h2>
<p class="First">NATRECOR<span class="Sup">®</span> is physically and/or chemically incompatible with injectable formulations of heparin, insulin, ethacrynate sodium, bumetanide, enalaprilat, hydralazine, and furosemide. Do not co-administer these drugs with NATRECOR<span class="Sup">®</span> through the same IV catheter. The preservative sodium metabisulfite is incompatible with NATRECOR<span class="Sup">®</span>. Do not administer injectable drugs that contain sodium metabisulfite in the same infusion line as NATRECOR<span class="Sup">®</span>. Flush the catheter between administration of NATRECOR<span class="Sup">®</span> and incompatible drugs.</p>
<p>NATRECOR<span class="Sup">®</span> binds to heparin and therefore could bind to the heparin lining of a heparin-coated catheter, decreasing the amount of NATRECOR<span class="Sup">®</span> delivered to the patient for some period of time. Therefore, do not administer NATRECOR<span class="Sup">®</span> through a central heparin-coated catheter. Concomitant administration of a heparin infusion through a separate catheter is acceptable.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">NATRECOR<span class="Sup">®</span> (nesiritide) is provided in a sterile, single-use vial. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">NATRECOR<span class="Sup">®</span> is contraindicated in patients with:</p>
<ul class="Disc">
<li>                       Persistent systolic blood pressure &lt;100 mm Hg prior to therapy because of an increased risk of symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic shock</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">NATRECOR<span class="Sup">®</span> may cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In the ASCEND-HF trial, the incidence of symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was 7.1% in NATRECOR<span class="Sup">®</span>-treated patients compared to 4.0% in placebo-treated patients on a background of standard care. The risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may be increased by the concomitant use of NATRECOR<span class="Sup">®</span> with drugs affecting the renin-angiotensin system (i.e., angiotensin receptor blockers and/or angiotensin-converting enzyme inhibitors) or other afterload reducers. In the VMAC trial, in patients given the recommended dose (2 mcg/kg bolus followed by a 0.01 mcg/kg/min infusion) or the adjustable dose, the incidence of symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the first 24 hours was similar for NATRECOR<span class="Sup">®</span> (4%) and IV nitroglycerin (5%). When <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred, however, the duration of symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was longer with NATRECOR<span class="Sup">®</span> (mean duration was 2.2 hours) than with nitroglycerin (mean duration was 0.7 hours).</p>
<p>Administer NATRECOR<span class="Sup">®</span> only in settings where blood pressure can be monitored closely and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> aggressively treated. Reduce the dose of or discontinue NATRECOR<span class="Sup">®</span> in patients who develop <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a>]</span>.</p>
<p>Avoid administration of NATRECOR<span class="Sup">®</span> in patients suspected of having, or known to have, low cardiac filling pressures.</p>
<p>NATRECOR<span class="Sup">®</span> is not recommended for patients for whom vasodilating agents are not appropriate, such as patients with significant valvular stenosis, restrictive or <span class="product-label-link" type="condition" conceptid="316428" conceptname="Hypertrophic obstructive cardiomyopathy">obstructive cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span>, <span class="product-label-link" type="condition" conceptid="318450" conceptname="Cardiac tamponade">pericardial tamponade</span>, or other conditions in which <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> is dependent upon venous return, or for patients suspected to have low cardiac filling pressures <span class="Italics">[see <a href="#s4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Worsening of Renal Function</h2>
<p class="First">                         NATRECOR<span class="Sup">®</span> may decrease renal function as judged by increases in serum creatinine. Monitor serum creatinine both during and after therapy has been completed. Monitor serum creatinine until values have stabilized. In patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> whose renal function may depend on the activity of the renin-angiotensin aldosterone system, treatment with NATRECOR<span class="Sup">®</span> may be associated with <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. When NATRECOR<span class="Sup">®</span> was initiated at doses higher than 0.01 mcg/kg/min (0.015 and 0.03 mcg/kg/min), there was an increased rate of elevated serum creatinine over baseline compared with standard therapies, although the rate of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and need for dialysis was not increased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">                          Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> following administration of NATRECOR<span class="Sup">®</span> have been reported.</p>
<p>                           These reactions are more likely to occur in individuals with a history of sensitivity to recombinant peptides. Before therapy with NATRECOR<span class="Sup">®</span> is instituted, careful inquiry should be made to determine whether the patient has had a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to other recombinant peptides. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to NATRECOR<span class="Sup">®</span> occurs, discontinue the drug. Some serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> may require treatment with epinephrine, oxygen, IV fluids, antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following are discussed in more detail in other sections of the labeling:</p>
<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>
</li></ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A causal relationship for NATRECOR<span class="Sup">®</span> cannot be reliably established in individual cases.</p>
<p>Adverse drug reactions that occurred at least ≥2% more frequently on NATRECOR<span class="Sup">®</span> than on placebo during the first 24 hours of infusion (excluding the ASCEND-HF study) are shown in Table 3.</p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3:	Adverse Drug Reactions<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> Reported at ≥2% Frequency During the First 24 Hours After the Start of Infusion in Long Infusion Trials<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> of NATRECOR<span class="Sup">®</span> at the Recommended Dose excluding ASCEND-HF Results</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left">System Organ Class<br>Adverse Reaction</th>
<th align="center">NATRECOR<span class="Sup">®</span> (N=331)<br>0.01 mcg/kg/min<br>% (n)<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</th>
<th align="center">Placebo (N=188)<br>% (n)<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Adverse drug reaction is defined as an adverse event with a frequency in the NATRECOR<span class="Sup">®</span> group ≥2% and occurred at a higher frequency than in the placebo group.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Trials in which NATRECOR<span class="Sup">®</span> was administered as a continuous infusion for ≥12 hours.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>704.339 [VMAC] and 704.341 [PROACTION].</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>704.311, 704.325 and 704.341 [PROACTION].</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td align="center">12 (41)</td>
<td align="center">4 (7)</td>
</tr>
<tr>
<td align="left"><span class="Bold">GI Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">3 (11)</td>
<td align="center">1 (2)</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center">3 (11)</td>
<td align="center">1 (2)</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">7 (24)</td>
<td align="center">6 (11)</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">2 (8)</td>
<td align="center">2 (3)</td>
</tr>
</tbody>
</table>
<p>Laboratory adverse drug reactions that occurred in ≥2% of patients and collected during the first 14 days after the start of NATRECOR<span class="Sup">®</span> infusion included: <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First">                                Worsening Renal Function</p>
<p>In the ASCEND-HF trial, through Day 30, the incidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> as measured by a &gt;25% decrease in glomerular filtration rate (calculated based on serum creatinine) was observed in 31.4% and 29.5% in the NATRECOR<span class="Sup">®</span> and placebo groups, respectively. Other metrics of decompensated renal function such as an increase in creatinine of &gt; 0.5 mg/dl, a 50% increase in creatinine or a value of ≥ 2 or 100% increase in creatinine were more frequent in the NATRECOR<span class="Sup">®</span> group. At 30 days post enrollment, more subjects in the NATRECOR<span class="Sup">®</span> group had elevated levels of creatinine of 50% greater than baseline compared to placebo 4.6% versus 3.3%. In the ASCEND-HF study there were relatively few subjects requiring either hemofiltration or dialysis.</p>
<p>In the PRECEDENT trial, the incidence of elevations in serum creatinine to &gt;0.5 mg/dL above baseline through Day 14 was higher in the NATRECOR<span class="Sup">®</span> 0.015 mcg/kg/min group (17%) and the NATRECOR<span class="Sup">®</span> 0.03 mcg/kg/min group (19%) than with standard therapy (11%). In the VMAC trial, through Day 30, the incidence of elevations in creatinine to &gt;0.5 mg/dL above baseline was 28% and 21% in the NATRECOR<span class="Sup">®</span> (2 mcg/kg bolus followed by 0.01 mcg/kg/min) and nitroglycerin groups, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First">                               Neutral Effect on Mortality</p>
<p>A meta-analysis performed of seven clinical trials demonstrated NATRECOR<span class="Sup">®</span> did not increase mortality in patients with acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span> (<span class="product-label-link" type="condition" conceptid="442310" conceptname="Acute heart failure">ADHF</span>) at Day 30 or Day 180 (see <a href="#figure1">Figures 1</a> and <a href="#figure2">2</a>). Data from seven studies in which 30-day data were collected are presented in Figure 1. The data depict hazard ratios (HR) and confidence intervals (CI) of mortality data for randomized and treated patients with NATRECOR<span class="Sup">®</span> relative to active or placebo controls through Day 30 for each of the seven individual studies along with the overall combined estimate (Studies 311, 325, 326, 329 [PRECEDENT], 339 [VMAC], 341 [PROACTION], and A093 [ASCEND-HF]).</p>
<p>Figure 1 (on logarithmic scale) also contains an estimate for the seven studies combined (n=8514). The results indicate that there is no increased mortality risk for NATRECOR<span class="Sup">®</span> at Day 30 (seven studies pooled: HR=0.99; 95% CI: 0.80, 1.22). The percentages are the Kaplan-Meier estimates.</p>
<a name="figure1"></a><table class="Noautorules" width="100%">
<col align="left" valign="top" width="100%">
<tfoot><tr><td align="left" colspan="1" valign="top">*Studies 704.311, 704.325, 704.326, 704.329, 704.339, 704.341 and ASCEND-HF</td></tr></tfoot>
<tbody class="Headless">
<tr><td align="left"><span class="Bold">Figure 1:	30-Day All-Cause Mortality Hazard Ratios</span></td></tr>
<tr><td align="left"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44c45bfe-461f-4398-8f20-ea771b2403ee&amp;name=natrecor-01.jpg"></td></tr>
</tbody>
</table>
<p>Figure 2 presents 180-day mortality hazard ratios from all six individual studies where 180-day data were collected (Studies 325, 326, 329, 339, 341 and A093 [ASCEND-HF]). The results indicate that with the addition of the ASCEND-HF data, there is no increased mortality risk for NATRECOR<span class="Sup">®</span> at Day 180 (six studies pooled: HR=0.98; 95% CI: 0.88, 1.10).</p>
<a name="figure2"></a><table class="Noautorules" width="100%">
<col align="left" valign="top" width="100%">
<tfoot><tr><td align="left" colspan="1" valign="top">*Studies 704.325, 704.326, 704.329, 704.339, 704.341 and ASCEND-HF</td></tr></tfoot>
<tbody class="Headless">
<tr><td align="left"><span class="Bold">Figure 2:	180-Day All-Cause Mortality Hazard Ratios</span></td></tr>
<tr><td align="left"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44c45bfe-461f-4398-8f20-ea771b2403ee&amp;name=natrecor-02.jpg"></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of NATRECOR<span class="Sup">®</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></li>
<li><span class="product-label-link" type="condition" conceptid="442120" conceptname="Injection site extravasation">Infusion site extravasation</span></li>
<li><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No trials specifically examining potential drug interactions with NATRECOR<span class="Sup">®</span> were conducted, although many concomitant drugs (including IV nitroglycerin) were used in clinical trials <span class="Italics">[see <a href="#s14">Clinical Studies (14)</a>]</span>. No drug interactions were detected except for an increase in symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in patients receiving afterload reducers or affecting the renin-angiotensin system (i.e., ARBs and/or ACE inhibitors).</p>
<p>The co-administration of NATRECOR<span class="Sup">®</span> with nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C</p>
<p>It is not known whether NATRECOR<span class="Sup">®</span> can cause fetal harm when administered to pregnant women or if it can affect reproductive capacity. A developmental reproductive toxicology study was conducted in pregnant rabbits using doses up to 1440 mcg/kg/day given by constant infusion for 13 days. At this level of exposure (based on AUC, approximately 70 × human exposure at the recommended dose) no adverse effects on live births or fetal development were observed. NATRECOR<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies any possible risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of NATRECOR<span class="Sup">®</span> in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients in clinical trials treated with NATRECOR<span class="Sup">®</span> (n=4505), 52% were 65 years or older and 27% were 75 years or older. No overall differences in effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. Some older individuals may be more sensitive to the effect of NATRECOR<span class="Sup">®</span> than younger individuals.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> with NATRECOR<span class="Sup">®</span> therapy has been reported and is primarily the result of either a miscalculated NATRECOR<span class="Sup">®</span> dose or a mechanical error such as an infusion-pump malfunction or an infusion-pump programming error. The most frequently reported adverse event reported with NATRECOR<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, which may be symptomatic and may persist for several hours. Asymptomatic hypotensive events may resolve with drug stoppage. In some cases <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may persist for several hours beyond discontinuation. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, discontinue NATRECOR<span class="Sup">®</span> and support blood pressure <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">NATRECOR<span class="Sup">®</span> (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from <span class="Italics">E. coli</span> using recombinant DNA technology. Nesiritide has a molecular weight of 3464 g/mol and an empirical formula of C<span class="Sub">143</span>H<span class="Sub">244</span>N<span class="Sub">50</span>O<span class="Sub">42</span>S<span class="Sub">4</span>. Nesiritide has the same 32 amino acid sequence as the endogenous peptide, which is produced by the ventricular myocardium.</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44c45bfe-461f-4398-8f20-ea771b2403ee&amp;name=natrecor-03.jpg"></div>
<p>NATRECOR<span class="Sup">®</span> is formulated as the citrate salt of rhBNP, and is provided in a sterile, single-use vial. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution. The quantitative composition of the lyophilized drug per vial is: nesiritide 1.58 mg, citric acid monohydrate 2.1 mg, mannitol 20.0 mg, and sodium citrate dihydrate 2.94 mg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Human BNP (hBNP) is secreted by the ventricular myocardium in response to stretch and exists in several isoforms in the human body. Elevated levels of BNP have been associated with advanced <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and are considered to be a compensatory mechanism in this disease. Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritide has been shown to relax isolated human arterial and venous tissue preparations that were precontracted with either endothelin-1 or the alpha-adrenergic agonist, phenylephrine.</p>
<p>In animals, nesiritide had no effects on cardiac contractility or on measures of cardiac electrophysiology such as atrial and ventricular effective refractory times or atrioventricular node conduction.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">With a dosing regimen of NATRECOR<span class="Sup">®</span> of 2 mcg/kg IV bolus followed by an intravenous infusion dose of 0.01 mcg/kg/min, Table 4 and Figure 3 summarize the changes in the VMAC trial in PCWP and other measures during the first 3 hours.</p>
<a name="table4"></a><table width="80%">
<caption><span>Table 4:	Mean Hemodynamic Change from Baseline in the VMAC study</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th align="left" valign="top">Effects at 3 Hours</th>
<th align="center">Placebo<br>(n=62)</th>
<th align="center">Nitroglycerin<br>(n=60)</th>
<th align="center">NATRECOR<span class="Sup">®</span><br>(n=124)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Based on all treated patients: placebo n=142, nitroglycerin n=143, NATRECOR<span class="Sup">®</span> n=204</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>p &lt;0.05 compared to placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left">Pulmonary capillary wedge pressure (mm Hg)</td>
<td align="center">-2.0</td>
<td align="center">-3.8</td>
<td align="center">-5.8<a href="#footnote-6" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Right atrial pressure (mm Hg)</td>
<td align="center">0.0</td>
<td align="center">-2.6</td>
<td align="center">-3.1<a href="#footnote-6" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">Cardiac index</span> (L/min/M<span class="Sup">2</span>)</td>
<td align="center">0.0</td>
<td align="center">0.2</td>
<td align="center">0.1</td>
</tr>
<tr class="Botrule">
<td align="left">Mean pulmonary artery pressure (mm Hg)</td>
<td align="center">-1.1</td>
<td align="center">-2.5</td>
<td align="center">-5.4<a href="#footnote-6" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> (dynes∙sec∙cm<span class="Sup">-5</span>)</td>
<td align="center">-44</td>
<td align="center">-105</td>
<td align="center">-144</td>
</tr>
<tr class="Last">
<td align="left">Systolic blood pressure<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> (mm Hg)</td>
<td align="center">-2.5</td>
<td align="center">-5.7<a href="#footnote-6" class="Sup">†</a>
</td>
<td align="center">-5.6<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 3:	PCWP through 3 Hours in VMAC</span></p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44c45bfe-461f-4398-8f20-ea771b2403ee&amp;name=natrecor-04.jpg"></div>
<p>With this dosing regimen, 60% of the 3-hour effect on PCWP reduction is achieved within 15 minutes after the bolus, reaching 95% of the 3-hour effect within 1 hour. Approximately 70% of the 3-hour effect on SBP reduction is reached within 15 minutes. The pharmacodynamic (PD) half-life of the onset and offset of the hemodynamic effect of NATRECOR<span class="Sup">®</span> is longer than what the PK half-life of 18 minutes would predict. Longer infusions may exaggerate the discrepancy from onset and offset effects. For example, in patients who developed symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the VMAC (Vasodilation in the Management of Acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>) trial, half of the recovery of SBP toward the baseline value after discontinuation or reduction of the dose of NATRECOR<span class="Sup">®</span> was observed in about 60 minutes. When higher doses of NATRECOR<span class="Sup">®</span> were infused, the duration of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was sometimes several hours.</p>
<p>No rebound increase to levels above baseline state was observed. There was also no evidence of <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span> to the hemodynamic effects of NATRECOR<span class="Sup">®</span> in the clinical trials.</p>
<p>In the VMAC trial, in which the use of diuretics was not restricted, the mean change in volume status (output minus input) during the first 24 hours in the nitroglycerin and NATRECOR<span class="Sup">®</span> groups was similar: 1279 ± 1455 mL and 1257 ± 1657 mL, respectively.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First">Distribution</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (HF), NATRECOR<span class="Sup">®</span> administered intravenously by infusion or bolus exhibits biphasic disposition from the plasma. The mean terminal elimination half-life (t<span class="Sub">1/2</span>) of nesiritide is approximately 18 minutes and was associated with approximately 2/3 of the area-under-the-curve (AUC). The mean initial elimination phase was estimated to be approximately 2 minutes. In these patients, the mean volume of distribution of the central compartment (Vc) of nesiritide was estimated to be 0.073 L/kg, the mean steady-state volume of distribution (Vss) was 0.19 L/kg, and the mean clearance (CL) was approximately 9.2 mL/min/kg. At steady state, plasma BNP levels increase from baseline endogenous levels by approximately 3-fold to 6-fold with NATRECOR<span class="Sup">®</span> infusion doses ranging from 0.01 to 0.03 mcg/kg/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First">Metabolism and Excretion</p>
<p>The mechanism of elimination of nesiritide has not been studied specifically in humans.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First">Special Populations</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Clinical data suggest that dose adjustment is not required in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The effects of nesiritide on PCWP, <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> (CI), and systolic blood pressure (SBP) were not significantly different in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> (baseline serum creatinine ranging from 2 mg/dL to 4.3 mg/dL), and patients with normal renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.2"></a><p></p>
<p class="First"><span class="Italics">Body Weight</span></p>
<p>The population pharmacokinetic (PK) analyses carried out to determine the effects of demographics and clinical variables on PK parameters showed that clearance of nesiritide is proportional to body weight, supporting the administration of weight-adjusted dosing of nesiritide (i.e., administration on a mcg/kg/min basis).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.3"></a><p></p>
<p class="First"><span class="Italics">Age, Gender, Race/Ethnicity</span></p>
<p>Nesiritide clearance was not influenced significantly by age, gender, or race/ethnicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.4"></a><p></p>
<p class="First"><span class="Italics">Severity of HF</span></p>
<p>Nesiritide clearance was not influenced significantly by baseline endogenous hBNP concentration, severity of HF (as indicated by baseline PCWP, baseline CI, or New York Heart Association [NYHA] classification).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First">Effects of Concomitant Medications</p>
<p>The co-administration of NATRECOR<span class="Sup">®</span> with enalapril did not have significant effects on the PK of NATRECOR<span class="Sup">®</span>. The PK effect of co-administration of NATRECOR<span class="Sup">®</span> with other IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated. During clinical studies, NATRECOR<span class="Sup">®</span> was administered concomitantly with other medications, including: diuretics, digoxin, oral ACE inhibitors, anticoagulants, oral nitrates, statins, class III antiarrhythmic agents, beta-blockers, dobutamine, calcium channel blockers, angiotensin II receptor antagonists, and dopamine. Although no PK interactions were specifically assessed, there did not appear to be evidence suggesting any clinically significant PK interaction.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NON-CLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential or the effect on fertility of nesiritide. Nesiritide did not increase the frequency of mutations when used in an <span class="Italics">in vitro</span> bacterial cell assay (Ames test). No other genotoxicity studies were performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">NATRECOR<span class="Sup">®</span> has been studied in 11 clinical trials including 4505 patients with HF (NYHA class II–III 56%, NYHA class IV 27%; mean age 64 years, women 32%). There were six randomized, multi-center, placebo- or active-controlled studies (comparative agents included nitroglycerin, dobutamine, milrinone, nitroprusside, or dopamine) in which 4269 patients with decompensated HF received continuous infusions of NATRECOR<span class="Sup">®</span> at doses ranging from 0.01 to 0.03 mcg/kg/min. Of these patients, the majority (n=3358, 79%) received the NATRECOR<span class="Sup">®</span> infusion for at least 24 hours; 2182 (51%) received NATRECOR<span class="Sup">®</span> for 24 to 48 hours, and 1176 (28%) received NATRECOR<span class="Sup">®</span> for greater than 48 hours.</p>
<p>In the initial five of these six controlled trials, NATRECOR<span class="Sup">®</span> was used alone or in conjunction with other standard therapies, including diuretics (79%), digoxin (62%), oral ACE inhibitors (55%), anticoagulants (38%), oral nitrates (32%), statins (18%), class III antiarrhythmic agents (16%), beta-blockers (15%), dobutamine (15%), calcium channel blockers (11%), angiotensin II receptor antagonists (6%), and dopamine (4%).</p>
<p>In the ASCEND-HF trial (<span class="Bold">A</span>cute <span class="Bold">S</span>tudy of <span class="Bold">C</span>linical <span class="Bold">E</span>ffectiveness of <span class="Bold">N</span>esiritide in patients with <span class="Bold">D</span>ecompensated <span class="Bold">H</span>eart <span class="Bold">F</span>ailure), NATRECOR<span class="Sup">®</span> was used alone or in conjunction with other standard therapies. Most patients (99.4%) received diuretic medications in conjunction with NATRECOR<span class="Sup">®</span>, with the most commonly used diuretic being furosemide (55%). The following standard therapies were used in ≥2% of patients: beta-blockers (72%), aspirin (64%); oral ACE inhibitors (60%), statins (50%), aldosterone antagonists (48%), digoxin/digitalis glycoside (39%), oral or topical nitrates (30%), oral anticoagulants (29%), clopidogrel/thienopyridine (21%), angiotensin receptor antagonists (19%), antiarrhythmic agents (16%), IV nitroglycerin (16%); calcium channel blockers (13%), hydralazine (11%), dobutamine (8%), dopamine (5%), alpha blockers (4%), IV opiates (5%), and NSAIDs (4%). The following standard therapies were used in &lt;2% of patients: COX2 inhibitors, milrinone, epinephrine, levosimendan, nitroprusside, norepinephrine, phenylephrine, and vasopressin.</p>
<p>NATRECOR<span class="Sup">®</span> has been studied in a broad range of patients, including the elderly (53% &gt;65 years of age), women (33%), minorities (17% black), and patients with a history of significant morbidities such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (71%), previous <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (38%), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (43%), <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>/flutter (37%), <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>/<span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span> (10%), and preserved systolic function (20%). In trials other than the ASCEND-HF trial, NATRECOR<span class="Sup">®</span> was also studied in patients with nonsustained <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (25%) and patients with <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndromes</span> less than 7 days before the start of NATRECOR<span class="Sup">®</span> (4%).</p>
<p>The VMAC (Vasodilation in the Management of Acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>) trial was a randomized, double-blind study of 489 patients (246 patients requiring a right heart catheter, 243 patients without a right heart catheter) who required hospitalization for management of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> at rest due to acutely decompensated HF. The study compared the effects of NATRECOR<span class="Sup">®</span>, placebo, and IV nitroglycerin when added to background therapy (IV and oral diuretics, non-IV cardiac medications, dobutamine, and dopamine). Patients with <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, preserved systolic function, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> were not excluded. The primary endpoints of the study were the change from baseline in PCWP and the change from baseline in patients' <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, evaluated after three hours. Close attention was also paid to the occurrence and persistence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, given nesiritide's relatively long (compared to nitroglycerin) PK and PD half-life.</p>
<p>NATRECOR<span class="Sup">®</span> was administered as a 2 mcg/kg bolus over approximately 60 seconds, followed by a continuous fixed dose infusion of 0.01 mcg/kg/min. After the 3-hour placebo-controlled period, patients receiving placebo crossed over to double-blinded active therapy with either NATRECOR<span class="Sup">®</span> or nitroglycerin. The nitroglycerin dose was titrated at the physician's discretion. A subset of patients in the VMAC trial with central hemodynamic monitoring who were treated with NATRECOR<span class="Sup">®</span> (62 of 124 patients) were allowed dose increases of NATRECOR<span class="Sup">®</span> after the first 3 hours of treatment if the PCWP was ≥20 mm Hg and the SBP was ≥100 mm Hg. Dose increases of a 1 mcg/kg bolus followed by an increase of the infusion dose by 0.005 mcg/kg/min were allowed every 3 hours, up to a maximum dose of 0.03 mcg/kg/min. Overall, 23 patients in this subset had the dose of NATRECOR<span class="Sup">®</span> increased in the VMAC trial.</p>
<p>In the VMAC study, patients receiving NATRECOR<span class="Sup">®</span> reported greater improvement in their <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> at 3 hours than patients receiving placebo (p=0.034).</p>
<p>In the dose-response study, patients receiving both doses of NATRECOR<span class="Sup">®</span> reported greater improvement in <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> at 6 hours than patients receiving placebo.</p>
<p>NATRECOR<span class="Sup">®</span> was also studied in a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of NATRECOR<span class="Sup">®</span> compared with placebo the ASCEND-HF Study, which was a trial where both arms were administered in addition to standard care, in patients with <span class="product-label-link" type="condition" conceptid="442310" conceptname="Acute heart failure">ADHF</span>. The study was divided into a screening phase, a double-blind treatment phase, and a follow-up phase, including a Day 30 visit and a telephone contact at Day 180. Patients who qualified for the study were ≥18 years of age, hospitalized for the management of <span class="product-label-link" type="condition" conceptid="442310" conceptname="Acute heart failure">ADHF</span> or diagnosed with <span class="product-label-link" type="condition" conceptid="442310" conceptname="Acute heart failure">ADHF</span> within 48 hours after being hospitalized for another reason. They were randomized to receive either NATRECOR<span class="Sup">®</span> as a continuous IV infusion at 0.010 mcg/kg/min with or without an initial 2 mcg/kg bolus (at the discretion of the physician) or a matching placebo bolus and infusion.</p>
<p>The primary objective of ASCEND-HF was to evaluate whether treatment with NATRECOR<span class="Sup">®</span> compared to placebo improved patient outcomes (as measured by a reduction in the composite of HF rehospitalization and all-cause mortality from randomization through Day 30) or HF symptoms (as measured by patient self-assessed Likert <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> scale which included Markedly Better, Moderately Better, Minimally Better, No Change, Minimally Worse, Moderately Worse and Markedly Worse at 6 hours and 24 hours after NATRECOR<span class="Sup">®</span> initiation).</p>
<p>A total of 7141 patients were randomized of which 7007 patients took at least one dose of study medication (modified intent-to-treat population) and received treatment for 24 to 168 hours (7 days), if the patient's clinical condition warranted continued treatment for <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> or <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span>, at the physician's discretion. The median treatment duration was 42.9 hours for the placebo group and 40.8 hours for the NATRECOR<span class="Sup">®</span> group. The patients' mean age was 65.5 years. The patient population was 65.8% male, 55.9% Caucasian, 24.7% Asian and 15.1% Black or African American.</p>
<p>The incidence rate for the composite of HF rehospitalization and all-cause mortality from randomization through Day 30 was 9.4% in the NATRECOR<span class="Sup">®</span> group compared with 10.1% in the placebo group. The difference was not statistically significant (p=0.313). The self-assessed <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> results did not meet the pre-specified criteria for statistical significance (p ≤0.005 for both or p ≤0.0025 for either) at either time point.</p>
<p>A total of 273 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were reported during the first 30 days after therapy and 876 (12.5%) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were reported from randomization through Day 180, 429 (12.3%) patients in the NATRECOR<span class="Sup">®</span> group and 447 (12.7%) patients in the placebo group. Approximately 65% of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> at 180 days were cardiovascular (mostly worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>). There was no statistically significant difference between treatment groups (p=0.5).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NATRECOR<span class="Sup">®</span> (nesiritide) is provided as a sterile lyophilized powder in 1.5 mg, single-use vials. Each carton contains one vial and is available in the following package:</p>
<p>1 vial/carton (NDC 65847-205-25)</p>
<p>Store below 25°C. Do not freeze. Keep the vial in the outer carton in order to protect from light.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients of the potential benefits and risks of NATRECOR<span class="Sup">®</span>. Advise patients to notify their physician or healthcare professional if they have symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Product of Austria</p>
<p>Manufactured for: <br>Scios LLC<br>Titusville, NJ 08560</p>
<p>Copyright 2007 Scios LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1.5 mg Vial Carton</span></p>
<p>Scios LLC<br>NDC 65847-205-25</p>
<p><span class="Bold">NATRECOR</span><span class="Sup">®</span><br>(nesiritide)<br>for Injection</p>
<p><span class="Bold">1.5 mg<br>Single-use vial</span></p>
<p><span class="Bold">For IV Infusion Only</span></p>
<p>Store below 25°C. Do not freeze. Keep the vial<br>in the outer carton in order to protect from light.</p>
<p>Rx only</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1.5 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44c45bfe-461f-4398-8f20-ea771b2403ee&amp;name=natrecor-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NATRECOR 		
					</strong><br><span class="contentTableReg">nesiritide injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65847-205</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NESIRITIDE</strong> (NESIRITIDE) </td>
<td class="formItem">NESIRITIDE</td>
<td class="formItem">1.5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">20 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">2.1 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem">2.94 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65847-205-25</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020920</td>
<td class="formItem">08/01/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Scios LLC
							(015904436)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hospira, Inc.</td>
<td class="formItem"></td>
<td class="formItem">030606222</td>
<td class="formItem">MANUFACTURE(65847-205)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sandoz GmbH, BiochemiestraB 10</td>
<td class="formItem"></td>
<td class="formItem">300220969</td>
<td class="formItem">MANUFACTURE(65847-205), ANALYSIS(65847-205)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sandoz GmbH, A-6330 Schaftenau</td>
<td class="formItem"></td>
<td class="formItem">301698247</td>
<td class="formItem">MANUFACTURE(65847-205)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e6d04dea-cced-479f-bd5f-74f4fd677e00</div>
<div>Set id: 44c45bfe-461f-4398-8f20-ea771b2403ee</div>
<div>Version: 9</div>
<div>Effective Time: 20131130</div>
</div>
</div> <div class="DistributorName">Scios LLC</div></p>
</body></html>
